Top Markets
Coin of the day
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc.

ARTV
Hisse Senetlerindeki Sıralama #12869
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm... Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Hisse Fiyatı
$11.09
Son senkronizasyon: 2026-08-28
Piyasa Değeri
$542.19M
Değişim (1 gün)
-7.12%
Değişim (1 yıl)
252.06%
Ülke
US
Ticaret Artiva Biotherapeutics, Inc. (ARTV)

Kategori

Artiva Biotherapeutics, Inc. (ARTV) için temettü verimi geçmişi
Artiva Biotherapeutics, Inc. (hisse sembolü: ARTV) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Artiva Biotherapeutics, Inc. (ARTV) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)
Şirket Temettü Verimi Ülke
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH